SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia

Detalhes bibliográficos
Autor(a) principal: Rocha, Diana Isabel Soares Silva Moreira
Data de Publicação: 2022
Outros Autores: Abreu, Vasco, Novo, Ana, Costa, Ana Rita, Almeida, Mónica
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.24950/rspmi.227
Resumo: The first vaccines against the SARS-CoV-2 virus appeared one year after the WHO declared COVID-19 as a pandemic, with data from United Kingdom and United States of America (USA) reporting a reduction in hospitalization about 67% e 94%, with one or two doses of an approved vaccine. In February 2021, the first cases of thrombocytopenia and thrombosis at uncommon sites (cerebral venous sinus and splanchnic venous thrombosis) induced by the vaccines were described. The incidence is still unknown, but early studies in the USA suggest an incidence of 1 in 533 333/vaccinated individuals, and this is probably underestimated. Although uncommon, it is a serious adverse effect with a high mortality rate, estimated at 20%. This case report highlights the need for a high level of suspicion, which may change the prognosis of some of these patients.
id RCAP_8aea5e84fb31ede35dc27a31362e7920
oai_identifier_str oai:oai.revista.spmi.pt:article/227
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling SARS-CoV-2 Vaccine–Induced Immune Thrombotic ThrombocytopeniaTrombocitopenia Trombótica Imune Induzida pela Vacina Contra a COVID-19COVID/prevenção e controloSARS-CoV-2Trombocitopenia/induzida quimicamenteTrombose VenosaVacina contra COVID-19/efeitos adversosCOVID-19 Vaccines/adverse effectsCOVID-19/prevention & controlSARS-CoV-2Venous ThrombosisThrombocytopenia/chemically inducedThe first vaccines against the SARS-CoV-2 virus appeared one year after the WHO declared COVID-19 as a pandemic, with data from United Kingdom and United States of America (USA) reporting a reduction in hospitalization about 67% e 94%, with one or two doses of an approved vaccine. In February 2021, the first cases of thrombocytopenia and thrombosis at uncommon sites (cerebral venous sinus and splanchnic venous thrombosis) induced by the vaccines were described. The incidence is still unknown, but early studies in the USA suggest an incidence of 1 in 533 333/vaccinated individuals, and this is probably underestimated. Although uncommon, it is a serious adverse effect with a high mortality rate, estimated at 20%. This case report highlights the need for a high level of suspicion, which may change the prognosis of some of these patients.Um ano depois de declarada pandemia pela Organização Mundial da Saúde, surgiram as primeiras vacinas contra o vírus SARS-CoV-2. Na literatura, dados referentes ao Reino Unido e aos Estados Unidos da América (EUA) sugerem que a vacinação - uma ou duas doses – reduziu as hospitalizações entre 67% e 94%. Em fevereiro de 2021 foram descritos os primeiros casos de trombocitopenia e trombose em locais atípicos, nomeadamente a nível do seio venoso cerebral e na circulação venosa esplâncnica, associadas à toma da vacina. Os primeiros estudos nos EUA sugerem uma incidência (provavelmente subestimada) de 1 em 533 333/indivíduos vacinados. Apesar de incomum, é um efeito adverso grave com alta taxa de mortalidade, estimada em 20%, em parte pelo diagnóstico tardio, pois a clínica inicial é muitas vezes inespecífica e frustre. Este relato de caso salienta a necessidade de um elevado índice de suspeição ab initio, que pode mudar o prognóstico destes doentes.Sociedade Portuguesa de Medicina Interna2022-12-19info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.24950/rspmi.227https://doi.org/10.24950/rspmi.227Internal Medicine; Vol. 29 No. 4 (2022): Outubro/Dezembro; 267-271Medicina Interna; Vol. 29 N.º 4 (2022): Outubro/Dezembro; 267-2712183-99800872-671Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spmi.pt/index.php/rpmi/article/view/227https://revista.spmi.pt/index.php/rpmi/article/view/227/922Direitos de Autor (c) 2022 Medicina Internainfo:eu-repo/semantics/openAccessRocha, Diana Isabel Soares Silva MoreiraAbreu, VascoNovo, AnaCosta, Ana RitaAlmeida, Mónica2023-01-07T06:10:34Zoai:oai.revista.spmi.pt:article/227Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:28:51.634629Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
Trombocitopenia Trombótica Imune Induzida pela Vacina Contra a COVID-19
title SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
spellingShingle SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
Rocha, Diana Isabel Soares Silva Moreira
COVID/prevenção e controlo
SARS-CoV-2
Trombocitopenia/induzida quimicamente
Trombose Venosa
Vacina contra COVID-19/efeitos adversos
COVID-19 Vaccines/adverse effects
COVID-19/prevention & control
SARS-CoV-2
Venous Thrombosis
Thrombocytopenia/chemically induced
title_short SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
title_full SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
title_fullStr SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
title_full_unstemmed SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
title_sort SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
author Rocha, Diana Isabel Soares Silva Moreira
author_facet Rocha, Diana Isabel Soares Silva Moreira
Abreu, Vasco
Novo, Ana
Costa, Ana Rita
Almeida, Mónica
author_role author
author2 Abreu, Vasco
Novo, Ana
Costa, Ana Rita
Almeida, Mónica
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Rocha, Diana Isabel Soares Silva Moreira
Abreu, Vasco
Novo, Ana
Costa, Ana Rita
Almeida, Mónica
dc.subject.por.fl_str_mv COVID/prevenção e controlo
SARS-CoV-2
Trombocitopenia/induzida quimicamente
Trombose Venosa
Vacina contra COVID-19/efeitos adversos
COVID-19 Vaccines/adverse effects
COVID-19/prevention & control
SARS-CoV-2
Venous Thrombosis
Thrombocytopenia/chemically induced
topic COVID/prevenção e controlo
SARS-CoV-2
Trombocitopenia/induzida quimicamente
Trombose Venosa
Vacina contra COVID-19/efeitos adversos
COVID-19 Vaccines/adverse effects
COVID-19/prevention & control
SARS-CoV-2
Venous Thrombosis
Thrombocytopenia/chemically induced
description The first vaccines against the SARS-CoV-2 virus appeared one year after the WHO declared COVID-19 as a pandemic, with data from United Kingdom and United States of America (USA) reporting a reduction in hospitalization about 67% e 94%, with one or two doses of an approved vaccine. In February 2021, the first cases of thrombocytopenia and thrombosis at uncommon sites (cerebral venous sinus and splanchnic venous thrombosis) induced by the vaccines were described. The incidence is still unknown, but early studies in the USA suggest an incidence of 1 in 533 333/vaccinated individuals, and this is probably underestimated. Although uncommon, it is a serious adverse effect with a high mortality rate, estimated at 20%. This case report highlights the need for a high level of suspicion, which may change the prognosis of some of these patients.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-19
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.24950/rspmi.227
https://doi.org/10.24950/rspmi.227
url https://doi.org/10.24950/rspmi.227
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revista.spmi.pt/index.php/rpmi/article/view/227
https://revista.spmi.pt/index.php/rpmi/article/view/227/922
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2022 Medicina Interna
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2022 Medicina Interna
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
dc.source.none.fl_str_mv Internal Medicine; Vol. 29 No. 4 (2022): Outubro/Dezembro; 267-271
Medicina Interna; Vol. 29 N.º 4 (2022): Outubro/Dezembro; 267-271
2183-9980
0872-671X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130746572505088

Registros relacionados